missing translation for 'onlineSavingsMsg'
Learn More
Learn More
ER alpha/NR3A1 Antibody (33), Novus Biologicals™
Mouse Monoclonal Antibody has been used in 7 publications
Brand: Novus Biologicals NB300-560-0.025mg
This item is not returnable.
View return policy
Description
ER alpha/NR3A1 Monoclonal specifically detects ER alpha/NR3A1 in Human, Mouse, Rat, Avian, Bovine, Gerbil, Primate samples. It is validated for Western Blot, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Immunofluorescence.
Specifications
| ER alpha/NR3A1 | |
| Monoclonal | |
| 1 mg/mL | |
| Western Blot 4 μg/mL, Immunohistochemistry 1:20 - 1:100, Immunohistochemistry-Paraffin 1:10-1:500, Immunohistochemistry-Frozen 1:10-1:500, Immunofluorescence 10 μg/mL | |
| ER, ER alpha, Era, ER-alpha, ESRESRA, Estradiol receptor, estrogen receptor, estrogen receptor 1, estrogen receptor alpha, estrogen receptor alpha delta 3*4,56,7*/819-2 isoform, estrogen receptor alpha delta 4 +49 isoform, estrogen receptor alpha delta 4*5,6,7*/654 isoform, NR3A1DKFZp686N23123, Nuclear receptor subfamily 3 group A member 1 | |
| Mouse | |
| 67 kDa | |
| 0.025 mg | |
| Cancer, Cell Biology, Cell Cycle and Replication, Dendritic Cell Markers, GPCR, Neuroscience, Signal Transduction, Transcription Factors and Regulators | |
| 2099 | |
| Human | |
| Ascites |
| Western Blot | |
| 33 | |
| Unconjugated | |
| P03372 | |
| ESR1 | |
| Synthetic peptide corresponding to the residues E(247) V G M M K G G I R K D R R G(261) of the ER alpha DNA binding domain. | |
| Protein G purified | |
| RUO | |
| Primary | |
| Detects both the steroid occupied and unoccupied forms of the estrogen receptor (ER) alpha. This does not cross react with ER beta, androgen receptor, progesterone receptor, or glucocorticoid receptor. | |
| Store at -20°C. Avoid freeze/thaw cycles. | |
| IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction